MedTrace Logo

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

NCT03657355 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2019-09-19

No results posted yet for this study

Summary

This placebo- and active controlled study will investigate the abuse potential of ACT-541468 in healthy recreational drug users

Conditions

  • Healthy Recreational Drug Users

Interventions

DRUG

ACT-541468

ACT-541468 will be administered as 50 mg tablets for oral use.

DRUG

Suvorexant

Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.

DRUG

Zolpidem

Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.

DRUG

Placebo

Matching-placebo will be used.

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Idorsia Pharmaceuticals Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-07
Primary Completion
2019-08-08
Completion
2019-08-08
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03657355 on ClinicalTrials.gov